abstract

Extended-release and delayed-release oral formulations are designed to modify the presentation of an active pharmaceutical ingredient (API) within the gastrointestinal tract and commonly contain complex combinations of polymers, coating materials, fillers, binders, lubricants and other excipients. These formulation characteristics can create significant challenges during mass-spectrometric analysis, particularly through matrix-induced ion suppression or ion enhancement. The present study describes a proposed UPLC-MS/MS analytical strategy for the quantitative analysis of selected APIs in extended-release and delayed-release oral pharmaceutical formulations, with particular emphasis on matrix-effect evaluation, mitigation and stability-indicating capability. The analytical workflow comprised formulation characterisation, sample-preparation optimisation, reversed-phase UPLC separation, electrospray ionisation, tandem mass spectrometric detection, matrix-factor determination, internal-standard normalisation and forced-degradation studies. Matrix effects were evaluated using neat standards, post-extraction spiked samples and, where appropriate, post-column infusion. Forced degradation was performed under acidic, alkaline, oxidative, thermal, photolytic and humidity-related conditions to investigate separation of the intact API from degradation-related components. The proposed validation framework included specificity/selectivity, linearity, range, accuracy, precision, lower-range performance, robustness and solution stability. Illustrative numerical values are included in this manuscript solely to demonstrate the expected presentation of experimental data and must be replaced with experimentally generated results before publication. The study provides a practical framework for evaluating whether UPLC-MS/MS can deliver reliable quantitative performance in complex modified-release oral formulations while maintaining sufficient selectivity for impurity and degradation-product monitoring.